Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03155620 : Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
PhasePhase 2
AgesMin: 12 Months Max: 21 Years
Eligibility
Inclusion Criteria:

- ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients with recurrent or
refractory solid tumors (including non-Hodgkin lymphomas, histiocytoses [e.g.
Langerhans cell histiocytosis (LCH), juvenile xanthogranuloma (JXG), histiocytic
sarcoma], and central nervous system [CNS] tumors) are eligible; patients must have
had histologic verification of malignancy at original diagnosis or relapse except in
patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with
pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers
including alpha-fetoprotein or beta-HCG

- ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients must have a formalin
fixed paraffin embedded (FFPE) tumor sample available for MATCH study testing from a
biopsy or surgery that was performed at any point after initial tumor
recurrence/progression, or be planned to have a procedure to obtain such a sample that
is considered to be of potential benefit by the treating clinicians; a tumor sample
from a clinically performed diagnostic (pre-treatment) biopsy will be acceptable for
enrollment onto pediatric MATCH for children with diffuse intrinsic pontine gliomas
(DIPG, brainstem gliomas)

- ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Karnofsky >= 50% for patients >
16 years of age and Lansky >= 50 for patients =< 16 years of age); Note: neurologic
deficits in patients with CNS tumors must have been stable for at least 7 days prior
to study enrollment; patients who are unable to walk because of paralysis, but who are
up in a wheelchair, will be considered ambulatory for the purpose of assessing the
performance score

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: NOTE: patient does not need to meet all
subprotocol criteria at time of enrollment onto the APEC1621 screening protocol, but
will need to meet all criteria prior to enrollment on any assigned treatment
subprotocol; patients must be enrolled onto a subprotocol within 8 weeks (56 days) of
treatment assignment

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Karnofsky >= 50% for patients > 16 years
of age and Lansky >= 50 for patients =< 16 years of age); Note: neurologic deficits in
patients with CNS tumors must have been stable for at least 7 days prior to study
enrollment; patients who are unable to walk because of paralysis, but who are up in a
wheelchair, will be considered ambulatory for the purpose of assessing the performance
score

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of treatment with subprotocol
specified therapy, the patients must have radiographically measurable disease;
patients with neuroblastoma who do not have measurable disease but have iobenguane
(MIBG) positive (+) evaluable are eligible; measurable disease in patients with CNS
involvement is defined as tumor that is measurable in two perpendicular diameters on
magnetic resonance imaging (MRI) and visible on more than one slice

- Note: The following do not qualify as measurable disease:

- Malignant fluid collections (e.g., ascites, pleural effusions)

- Bone marrow infiltration except that detected by MIBG scan for neuroblastoma

- Lesions only detected by nuclear medicine studies (e.g., bone, gallium or
positron emission tomography [PET] scans) except as noted for neuroblastoma

- Elevated tumor markers in plasma or CSF

- Previously radiated lesions that have not demonstrated clear progression
post radiation

- Leptomeningeal lesions that do not meet the measurement requirements for
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of enrollment onto a
subprotocol, the following general criteria for initiation of therapy will be
required:

- Patients must have fully recovered from the acute toxic effects of all prior
anticancer therapy and must meet the following minimum duration from prior
anticancer directed therapy prior to enrollment to the subprotocol; if after the
required timeframe, the numerical eligibility criteria are met, e.g. blood count
criteria, the patient is considered to have recovered adequately

- Cytotoxic chemotherapy or other anticancer agents known to be
myelosuppressive: for agents not listed, the duration of this interval must
be discussed with the study chair and the study-assigned research
coordinator prior to enrollment

- >= 21 days after the last dose of cytotoxic or myelosuppressive
chemotherapy (42 days if prior nitrosourea)

- Anticancer agents not known to be myelosuppressive (e.g. not associated with
reduced platelet or absolute neutrophil counts [ANC]): >= 7 days after the
last dose of agent; for agents not listed, the duration of this interval
must be discussed with the study chair and the study-assigned research
coordinator prior to enrollment

- Antibodies: >= 21 days must have elapsed from infusion of last dose of
antibody, and toxicity related to prior antibody therapy must be recovered
to grade =< 1

- Corticosteroids: If used to modify immune adverse events related to prior
therapy, >= 14 days must have elapsed since last dose of corticosteroid

- Hematopoietic growth factors: >= 14 days after the last dose of a
long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth
factor; for agents that have known adverse events occurring beyond 7 days
after administration, this period must be extended beyond the time during
which adverse events are known to occur; the duration of this interval must
be discussed with the study chair and the study-assigned research
coordinator

- Interleukins, interferons and cytokines (other than hematopoietic growth
factors): >= 21 days after the completion of interleukins, interferon or
cytokines (other than hematopoietic growth factors)

- Stem cell infusions (with or without TBI):

- Allogeneic (non-autologous) bone marrow or stem cell transplant, or any
stem cell infusion including donor lymphocyte infusion (DLI) or boost
infusion: >= 84 days after infusion and no evidence of GVHD

- Autologous stem cell infusion including boost infusion: >= 42 days

- Cellular therapy: >= 42 days after the completion of any type of cellular
therapy (e.g. modified T cells, NK cells, dendritic cells, etc.)

- X-ray therapy (XRT)/External Beam Irradiation including Protons: >= 14 days
after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to
>= 50% of the pelvis; >= 42 days if other substantial bone marrow (BM)
radiation; note: radiation may not be delivered to "measurable disease"
tumor site(s) being used to follow response to subprotocol treatment

- Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42
days after systemically administered radiopharmaceutical therapy

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: For patients with solid tumors without
known bone marrow involvement:

- Peripheral absolute neutrophil count (ANC) >= 1000/mm^3

- Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving
platelet transfusions for at least 7 days prior to enrollment

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients with known bone marrow
metastatic disease will be eligible for study provided they meet the blood counts (may
receive transfusions provided they are not known to be refractory to red cell or
platelet transfusions); these patients will not be evaluable for hematologic toxicity

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Creatinine clearance or radioisotope
glomerular filtration rate (GFR) >= 70ml/min/1.73 m^2 or a serum creatinine based on
age/gender as follows:

- Age: 1 to < 2 years; maximum serum creatinine (mg/dL): male 0.6; female 0.6

- Age: 2 to < 6 years; maximum serum creatinine (mg/dL): male 0.8; female 0.8

- Age: 6 to < 10 years; maximum serum creatinine (mg/dL): male 1; female 1

- Age: 10 to < 13 years; maximum serum creatinine (mg/dL): male 1.2; female 1.2

- Age: 13 to < 16 years; maximum serum creatinine (mg/dL): male 1.5; female 1.4

- Age: >= 16 years; maximum serum creatinine (mg/dL): male 1.7; female 1.4

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Bilirubin (sum of conjugated +
unconjugated) =< 1.5 x upper limit of normal (ULN) for age

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: serum glutamate pyruvate transaminase
(SGPT) (alanine transferase [ALT]) =< 135 U/L (for the purpose of this study, the ULN
for SGPT is 45 U/L)

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact
capsules/tablets, unless otherwise specified in the subprotocol to which they are
assigned

- GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Agent specific limitations on prior
therapy will be included with specific treatment subprotocols

Exclusion Criteria:

- GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Pregnant or breast-feeding women will not
be entered on this study; pregnancy tests must be obtained in females who are
post-menarchal; males or females of reproductive potential may not participate unless
they have agreed to use an effective contraceptive method

- GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Concomitant medications

- Corticosteroids: at the time of consent and enrollment to regimen specific
subprotocols, patients receiving corticosteroids who have not been on a stable or
decreasing dose of corticosteroid for at least 7 days prior to enrollment to the
subprotocol will not be eligible; if used to modify immune adverse events related
to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid

- Investigational drugs: patients must meet criteria for prior therapy at the time
of consent and enrollment to a subprotocol; other investigational agents may not
be administered to patients while they are receiving study drug as part of a
subprotocol

- Anticancer agents: patients must meet criteria for prior therapy at the time of
consent and enrollment to a subprotocol; other investigational agents may not be
administered to patients while they are receiving study drug as part of a
subprotocol

- Anti-GVHD agents post-transplant: patients who are receiving cyclosporine,
tacrolimus or other agents to prevent graft-versus-host disease post bone marrow
transplant are not eligible

- GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have an uncontrolled
infection are not eligible

- GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have had a prior solid organ
transplant are not eligible

- GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Additional agent specific criteria will
be included with specific treatment subprotocols
LinksPermanent Link to THIS page: http://virtualtrials.com/nct/display1trial.cfm?nct=NCT03155620      |      Link to official Clinicaltrials.gov listing
Locations
Birmingham, Alabama
Facility: Children's Hospital of Alabama
Investigator: Elizabeth D. Alva
Contact: Elizabeth D. Alva
Click HERE to send email to this center

Mesa, Arizona
Facility: Cardon Children's Medical Center
Investigator: Erlyn C. Smith
Contact: Erlyn C. Smith
Click HERE to send email to this center

Phoenix, Arizona
Facility: Phoenix Childrens Hospital
Investigator: Jessica Boklan
Contact: Jessica Boklan Phone: 602-546-0920
Email not avaialable

Little Rock, Arkansas
Facility: Arkansas Children's Hospital
Investigator: David L. Becton
Contact: David L. Becton
Click HERE to send email to this center

Downey, California
Facility: Southern California Permanente Medical Group
Investigator: Robert M. Cooper
Contact: Robert M. Cooper Phone: 626-564-3455
Email not avaialable

Long Beach, California
Facility: Miller Children's and Women's Hospital Long Beach
Investigator: Pamela H. Kempert
Contact: Pamela H. Kempert
Click HERE to send email to this center

Los Angeles, California
Facility: Children's Hospital Los Angeles
Investigator: Leo Mascarenhas
Contact: Leo Mascarenhas
Click HERE to send email to this center

Madera, California
Facility: Children's Hospital Central California
Investigator: Vonda L. Crouse
Contact: Vonda L. Crouse
Click HERE to send email to this center

Oakland, California
Facility: Children's Hospital and Research Center at Oakland
Investigator: Carla B. Golden
Contact: Carla B. Golden
Click HERE to send email to this center

Oakland, California
Facility: Kaiser Permanente-Oakland
Investigator: Steven K. Bergstrom
Contact: Steven K. Bergstrom Phone: 510-891-3400
Email not avaialable

Palo Alto, California
Facility: Lucile Packard Children's Hospital Stanford University
Investigator: Sheri L. Spunt
Contact: Sheri L. Spunt
Click HERE to send email to this center

San Diego, California
Facility: Naval Medical Center -San Diego
Investigator: Shelton A. Viola
Contact: Shelton A. Viola Phone: 619-532-8712
Email not avaialable

Aurora, Colorado
Facility: Children's Hospital Colorado
Investigator: Margaret E. Macy
Contact: Margaret E. Macy
Click HERE to send email to this center

Hartford, Connecticut
Facility: Connecticut Children's Medical Center
Investigator: Michael S. Isakoff
Contact: Michael S. Isakoff
Click HERE to send email to this center

Wilmington, Delaware
Facility: Alfred I duPont Hospital for Children
Investigator: Scott M. Bradfield
Contact: Scott M. Bradfield Phone: 302-651-5755
Email not avaialable

Washington, District of Columbia
Facility: Children's National Medical Center
Investigator: Jeffrey S. Dome
Contact: Jeffrey S. Dome
Click HERE to send email to this center

Gainesville, Florida
Facility: University of Florida Health Science Center - Gainesville
Investigator: William B. Slayton
Contact: William B. Slayton
Click HERE to send email to this center

Hollywood, Florida
Facility: Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Investigator: Iftikhar Hanif
Contact: Iftikhar Hanif
Click HERE to send email to this center

Jacksonville, Florida
Facility: Nemours Children's Clinic-Jacksonville
Investigator: Scott M. Bradfield
Contact: Scott M. Bradfield
Click HERE to send email to this center

Miami, Florida
Facility: University of Miami Miller School of Medicine-Sylvester Cancer Center
Investigator: Julio C. Barredo
Contact: Julio C. Barredo Phone: 305-243-2647
Email not avaialable

Miami, Florida
Facility: Nicklaus Children's Hospital
Investigator: Enrique A. Escalon
Contact: Enrique A. Escalon
Click HERE to send email to this center

Orlando, Florida
Facility: Arnold Palmer Hospital for Children
Investigator: Vincent F. Giusti
Contact: Vincent F. Giusti Phone: 321-843-2584
Email not avaialable

Orlando, Florida
Facility: Nemours Children's Hospital
Investigator: Scott M. Bradfield
Contact: Scott M. Bradfield
Click HERE to send email to this center

Pensacola, Florida
Facility: Nemours Children's Clinic - Pensacola
Investigator: Scott M. Bradfield
Contact: Scott M. Bradfield
Click HERE to send email to this center

Tampa, Florida
Facility: Tampa General Hospital
Investigator: Juan F. Rico
Contact: Juan F. Rico Phone: 813-844-8113
Click HERE to send email to this center

Tampa, Florida
Facility: Saint Joseph's Hospital/Children's Hospital-Tampa
Investigator: Mark J. Mogul
Contact: Mark J. Mogul
Click HERE to send email to this center

Honolulu, Hawaii
Facility: Kapiolani Medical Center for Women and Children
Investigator: Wade T. Kyono
Contact: Wade T. Kyono Phone: 808-983-6090
Email not avaialable

Boise, Idaho
Facility: Saint Luke's Mountain States Tumor Institute
Investigator: Eugenia Chang
Contact: Eugenia Chang
Click HERE to send email to this center

Indianapolis, Indiana
Facility: Riley Hospital for Children
Investigator: Kamnesh R. Pradhan
Contact: Kamnesh R. Pradhan Phone: 800-248-1199
Email not avaialable

Indianapolis, Indiana
Facility: Saint Vincent Hospital and Health Care Center
Investigator: Bassem I. Razzouk
Contact: Bassem I. Razzouk Phone: 317-338-2194
Click HERE to send email to this center

Des Moines, Iowa
Facility: Blank Children's Hospital
Investigator: Wendy L. Woods-Swafford
Contact: Wendy L. Woods-Swafford
Click HERE to send email to this center

New Orleans, Louisiana
Facility: Ochsner Medical Center Jefferson
Investigator: Craig Lotterman
Contact: Craig Lotterman Phone: 504-842-3708
Email not avaialable

Baltimore, Maryland
Facility: University of Maryland/Greenebaum Cancer Center
Investigator: Teresa A. York
Contact: Teresa A. York Phone: 800-888-8823
Email not avaialable

Baltimore, Maryland
Facility: Sinai Hospital of Baltimore
Investigator: Jason M. Fixler
Contact: Jason M. Fixler Phone: 410-601-6120
Click HERE to send email to this center

Baltimore, Maryland
Facility: Johns Hopkins University/Sidney Kimmel Cancer Center
Investigator: Kenneth J. Cohen
Contact: Kenneth J. Cohen Phone: 410-955-8804
Click HERE to send email to this center

Boston, Massachusetts
Facility: Dana-Farber Cancer Institute
Investigator: Katherine A. Janeway
Contact: Katherine A. Janeway Phone: 877-442-3324
Email not avaialable

Ann Arbor, Michigan
Facility: C S Mott Children's Hospital
Investigator: Rajen Mody
Contact: Rajen Mody
Click HERE to send email to this center

Minneapolis, Minnesota
Facility: Children's Hospitals and Clinics of Minnesota - Minneapolis
Investigator: Michael K. Richards
Contact: Michael K. Richards
Click HERE to send email to this center

Minneapolis, Minnesota
Facility: University of Minnesota/Masonic Cancer Center
Investigator: Emily G. Greengard
Contact: Emily G. Greengard
Click HERE to send email to this center

Jackson, Mississippi
Facility: University of Mississippi Medical Center
Investigator: Anderson (Andy) B. Collier
Contact: Anderson (Andy) B. Collier Phone: 601-815-6700
Email not avaialable

Saint Louis, Missouri
Facility: Washington University School of Medicine
Investigator: Robert J. Hayashi
Contact: Robert J. Hayashi Phone: 800-600-3606
Click HERE to send email to this center

Saint Louis, Missouri
Facility: Mercy Hospital Saint Louis
Investigator: Bethany G. Sleckman
Contact: Bethany G. Sleckman Phone: 314-251-6770
Email not avaialable

Las Vegas, Nevada
Facility: University Medical Center of Southern Nevada
Investigator: Alan K. Ikeda
Contact: Alan K. Ikeda Phone: 702-384-0013
Email not avaialable

Las Vegas, Nevada
Facility: Children's Specialty Center of Nevada II
Investigator: Alan K. Ikeda
Contact: Alan K. Ikeda
Click HERE to send email to this center

Las Vegas, Nevada
Facility: Summerlin Hospital Medical Center
Investigator: Alan K. Ikeda
Contact: Alan K. Ikeda Phone: 702-384-0013
Email not avaialable

Lebanon, New Hampshire
Facility: Dartmouth Hitchcock Medical Center
Investigator: Sara Chaffee
Contact: Sara Chaffee Phone: 800-639-6918
Click HERE to send email to this center

Morristown, New Jersey
Facility: Morristown Medical Center
Investigator: Steven L. Halpern
Contact: Steven L. Halpern Phone: 973-971-5900
Email not avaialable

Buffalo, New York
Facility: Roswell Park Cancer Institute
Investigator: Clare J. Twist
Contact: Clare J. Twist Phone: 877-275-7724
Email not avaialable

New Hyde Park, New York
Facility: The Steven and Alexandra Cohen Children's Medical Center of New York
Investigator: Julie I. Krystal
Contact: Julie I. Krystal
Click HERE to send email to this center

New York, New York
Facility: Laura and Isaac Perlmutter Cancer Center at NYU Langone
Investigator: Sharon L. Gardner
Contact: Sharon L. Gardner Phone: 212-263-4434
Click HERE to send email to this center

Rochester, New York
Facility: University of Rochester
Investigator: Jeffrey R. Andolina
Contact: Jeffrey R. Andolina Phone: 585-275-5830
Email not avaialable

Syracuse, New York
Facility: State University of New York Upstate Medical University
Investigator: Philip M. Monteleone
Contact: Philip M. Monteleone Phone: 315-464-5476
Email not avaialable

Valhalla, New York
Facility: New York Medical College
Investigator: Jessica C. Hochberg
Contact: Jessica C. Hochberg Phone: 914-594-3794
Email not avaialable

Asheville, North Carolina
Facility: Mission Hospital-Memorial Campus
Investigator: Douglas J. Scothorn
Contact: Douglas J. Scothorn Phone: 828-213-4150
Email not avaialable

Chapel Hill, North Carolina
Facility: UNC Lineberger Comprehensive Cancer Center
Investigator: Stuart H. Gold
Contact: Stuart H. Gold Phone: 877-668-0683
Click HERE to send email to this center

Durham, North Carolina
Facility: Duke University Medical Center
Investigator: Susan G. Kreissman
Contact: Susan G. Kreissman Phone: 888-275-3853
Email not avaialable

Akron, Ohio
Facility: Children's Hospital Medical Center of Akron
Investigator: Steven J. Kuerbitz
Contact: Steven J. Kuerbitz
Click HERE to send email to this center

Cincinnati, Ohio
Facility: Cincinnati Children's Hospital Medical Center
Investigator: James I. Geller
Contact: James I. Geller
Click HERE to send email to this center

Cleveland, Ohio
Facility: Cleveland Clinic Foundation
Investigator: Aron Flagg
Contact: Aron Flagg Phone: 866-223-8100
Email not avaialable

Dayton, Ohio
Facility: Dayton Children's Hospital
Investigator: Ayman A. El-Sheikh
Contact: Ayman A. El-Sheikh
Click HERE to send email to this center

Toledo, Ohio
Facility: The Toledo Hospital/Toledo Children's Hospital
Investigator: Jamie L. Dargart
Contact: Jamie L. Dargart Phone: 419-824-1842
Email not avaialable

Oklahoma City, Oklahoma
Facility: University of Oklahoma Health Sciences Center
Investigator: Rene Y. McNall-Knapp
Contact: Rene Y. McNall-Knapp Phone: 405-271-8777
Click HERE to send email to this center

Portland, Oregon
Facility: Legacy Emanuel Children's Hospital
Investigator: Janice F. Olson
Contact: Janice F. Olson
Click HERE to send email to this center

Portland, Oregon
Facility: Oregon Health and Science University
Investigator: Suman Malempati
Contact: Suman Malempati Phone: 503-494-1080
Click HERE to send email to this center

Philadelphia, Pennsylvania
Facility: Children's Hospital of Philadelphia
Investigator: Elizabeth Fox
Contact: Elizabeth Fox
Click HERE to send email to this center

Philadelphia, Pennsylvania
Facility: Childrens Oncology Group
Investigator: Donald W. Parsons
Contact: Donald W. Parsons Phone: 713-798-1354
Email not avaialable

Pittsburgh, Pennsylvania
Facility: Children's Hospital of Pittsburgh of UPMC
Investigator: Jean M. Tersak
Contact: Jean M. Tersak
Click HERE to send email to this center

Providence, Rhode Island
Facility: Rhode Island Hospital
Investigator: Jennifer J. Greene Welch
Contact: Jennifer J. Greene Welch Phone: 401-444-1488
Email not avaialable

Greenville, South Carolina
Facility: BI-LO Charities Children's Cancer Center
Investigator: Nichole L. Bryant
Contact: Nichole L. Bryant
Click HERE to send email to this center

Sioux Falls, South Dakota
Facility: Sanford USD Medical Center - Sioux Falls
Investigator: Kayelyn J. Wagner
Contact: Kayelyn J. Wagner Phone: 605-312-3320
Click HERE to send email to this center

Knoxville, Tennessee
Facility: East Tennessee Childrens Hospital
Investigator: Ray C. Pais
Contact: Ray C. Pais Phone: 865-541-8266
Email not avaialable

Memphis, Tennessee
Facility: St. Jude Children's Research Hospital
Investigator: Alberto S. Pappo
Contact: Alberto S. Pappo
Click HERE to send email to this center

Nashville, Tennessee
Facility: The Children's Hospital at TriStar Centennial
Investigator: Haydar A. Frangoul
Contact: Haydar A. Frangoul
Click HERE to send email to this center

Nashville, Tennessee
Facility: Vanderbilt University/Ingram Cancer Center
Investigator: Scott C. Borinstein
Contact: Scott C. Borinstein Phone: 800-811-8480
Email not avaialable

Austin, Texas
Facility: Dell Children's Medical Center of Central Texas
Investigator: Amy C. Fowler
Contact: Amy C. Fowler
Click HERE to send email to this center

Dallas, Texas
Facility: Medical City Dallas Hospital
Investigator: Stanton C. Goldman
Contact: Stanton C. Goldman Phone: 972-566-5588
Email not avaialable

Dallas, Texas
Facility: UT Southwestern/Simmons Cancer Center-Dallas
Investigator: Theodore W. Laetsch
Contact: Theodore W. Laetsch Phone: 214-648-7097
Email not avaialable

Fort Worth, Texas
Facility: Cook Children's Medical Center
Investigator: Kelly L. Vallance
Contact: Kelly L. Vallance
Click HERE to send email to this center

Houston, Texas
Facility: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Investigator: Jodi Muscal
Contact: Jodi Muscal Phone: 713-798-1354
Click HERE to send email to this center

San Antonio, Texas
Facility: Children's Hospital of San Antonio
Investigator: Timothy C. Griffin
Contact: Timothy C. Griffin
Click HERE to send email to this center

San Antonio, Texas
Facility: University of Texas Health Science Center at San Antonio
Investigator: Anne-Marie R. Langevin
Contact: Anne-Marie R. Langevin Phone: 210-450-3800
Click HERE to send email to this center

Norfolk, Virginia
Facility: Childrens Hospital-King's Daughters
Investigator: Eric J. Lowe
Contact: Eric J. Lowe
Click HERE to send email to this center

Seattle, Washington
Facility: Seattle Children's Hospital
Investigator: Douglas S. Hawkins
Contact: Douglas S. Hawkins
Click HERE to send email to this center

Spokane, Washington
Facility: Providence Sacred Heart Medical Center and Children's Hospital
Investigator: Judy L. Felgenhauer
Contact: Judy L. Felgenhauer
Click HERE to send email to this center

Morgantown, West Virginia
Facility: West Virginia University Healthcare
Investigator: Stephan R. Paul
Contact: Stephan R. Paul Phone: 304-293-7374
Click HERE to send email to this center

Madison, Wisconsin
Facility: University of Wisconsin Hospital and Clinics
Investigator: Kenneth B. De Santes
Contact: Kenneth B. De Santes Phone: 800-622-8922
Email not avaialable

Milwaukee, Wisconsin
Facility: Children's Hospital of Wisconsin
Investigator: Paul D. Harker-Murray
Contact: Paul D. Harker-Murray Phone: 414-955-4727
Click HERE to send email to this center




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites